organization · Reporting owner
D&D Source of Life Holding Ltd.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REED'S, INC.REED · Entity 7963 | 10% owner | June 04, 2025 | June 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REED'S, INC.
Report date June 04, 2025 · Filed June 11, 2025
Jointly reported with Era Regenerative Medicine Ltd
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 28,214,789 |
Reported balance
After 2025-06-04 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-06-04 · Purchase · Acquired 1,075,269 · Balance 28,214,789 F1: D&D Source of Life Holding Ltd. ("D&D"), participated in the Registrant's PIPE transaction. F2: The purchase price per share was $0.93. F3: Includes 232,108 shares of common stock issuable upon exercise of currently exercisable warrants. F4: Era Regenerative Medicine Ltd.("ERM") holds all the shares in D&D. Dai Siqi, currently the sole director of ERM, has sole voting and dispositive power over the securities of the Registrant held directly by D&D. |
Filing footnotes · ownership attribution and instrument terms
F1: D&D Source of Life Holding Ltd. ("D&D"), participated in the Registrant's PIPE transaction.
F2: The purchase price per share was $0.93.
F3: Includes 232,108 shares of common stock issuable upon exercise of currently exercisable warrants.
F4: Era Regenerative Medicine Ltd.("ERM") holds all the shares in D&D. Dai Siqi, currently the sole director of ERM, has sole voting and dispositive power over the securities of the Registrant held directly by D&D.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2025 Filed Jun 11, 2025 20:36 UTC | REED'S, INC. REED · Entity 7963 | PurchaseCommon Stock | 1,075,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001641172-25-014725 · ownership.xml · nonDerivative · entry 1 Era Regenerative Medicine Ltd · CIK 0002053961 · 10% owner D&D Source of Life Holding Ltd. · CIK 0001979652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 28,214,789 F1 · kind: D&D Source of Life Holding Ltd. ("D&D"), participated in the Registrant's PIPE transaction. F2 · price: The purchase price per share was $0.93. F3 · balance_after: Includes 232,108 shares of common stock issuable upon exercise of currently exercisable warrants. F4 · ownership.nature: Era Regenerative Medicine Ltd.("ERM") holds all the shares in D&D. Dai Siqi, currently the sole director of ERM, has sole voting and dispositive power over the securities of the Registrant held directly by D&D. Read SEC document |
| November 19, 2024 Filed Dec 6, 2024 21:30 UTC | REED'S, INC. REED · Entity 7963 | OtherCommon Stock | 22,478,074 | $1.00 | $22,478,074.00 |
DisclosureSEC source: 0001493152-24-049087 · ownership.xml · nonDerivative · entry 1 DENG Shufen · CIK 0001980084 · Director · 10% owner D&D Source of Life Holding Ltd. · CIK 0001979652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 27,139,519 F1 · kind: On November 19, 2024, the Registrant and D&D Source of Life Holding, Ltd ("D&D) entered into an Exchange Agreement, whereby D&D exchanged all obligations due under outstanding notes, for an aggregate of 22,478,074 shares of common stock of the Registrant. F2 · ownership.nature: The securities reported herein are held directly by D&D. Shufen Deng is the sole shareholder and director of D&D and may be deemed to beneficially own the securities reported herein. F3 · ownership.nature: Shufen Deng disclaims beneficial ownership of the securities reported herein except to the extent of her pecuniary interest therein. Read SEC document |
| September 10, 2024 Filed Sep 13, 2024 23:27 UTC | REED'S, INC. REED · Entity 7963 | PurchaseCommon Stock | 3,268,795 | $1.50 | $4,903,192.50 |
DisclosureSEC source: 0001104659-24-099900 · tm2423784-2_4seq1.xml · nonDerivative · entry 2 DENG Shufen · CIK 0001980084 · Director · 10% owner D&D Source of Life Holding Ltd. · CIK 0001979652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 4,429,337 F1 · ownership.nature: The securities reported herein are held directly by D&D Source of Life Holding Ltd. ("D&D"). DENG Shufen is the sole shareholder of D&D and may be deemed to beneficially own the securities reported herein. F2 · ownership.nature: Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein except to the extent of its or her pecuniary interest therein. Read SEC document |
| May 25, 2023 Filed Sep 13, 2024 23:27 UTC | REED'S, INC. REED · Entity 7963 | PurchaseWarrants (Right to Purchase) · Derivative | 232,108 | $2.59 Strike: $2.50 | $599,999.18 |
DisclosureSEC source: 0001104659-24-099900 · tm2423784-2_4seq1.xml · derivative · entry 3 DENG Shufen · CIK 0001980084 · Director · 10% owner D&D Source of Life Holding Ltd. · CIK 0001979652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 232,108 Underlying: Common Stock · 232,108 shares Expires 2026-05-25 F1 · ownership.nature: The securities reported herein are held directly by D&D Source of Life Holding Ltd. ("D&D"). DENG Shufen is the sole shareholder of D&D and may be deemed to beneficially own the securities reported herein. F2 · ownership.nature: Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein except to the extent of its or her pecuniary interest therein. Read SEC document |
| May 25, 2023 Filed Sep 13, 2024 23:27 UTC | REED'S, INC. REED · Entity 7963 | PurchaseCommon Stock | 1,160,542 | $2.59 | $3,000,001.07 |
DisclosureSEC source: 0001104659-24-099900 · tm2423784-2_4seq1.xml · nonDerivative · entry 1 DENG Shufen · CIK 0001980084 · Director · 10% owner D&D Source of Life Holding Ltd. · CIK 0001979652 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnotes Disclosed balance after: 1,160,542 F1 · ownership.nature: The securities reported herein are held directly by D&D Source of Life Holding Ltd. ("D&D"). DENG Shufen is the sole shareholder of D&D and may be deemed to beneficially own the securities reported herein. F2 · ownership.nature: Each of the Reporting Persons disclaim beneficial ownership of the securities reported herein except to the extent of its or her pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.